Multicenter Registry on Inflammatory Myositis From the Rheumatology Society in Madrid, Spain: Descriptive Analysis

Nuño, Laura; Joven, Beatriz; Carreira, Patrícia; Maldonado, Valentina; Larena, Carmen; Llorente, Irene; Tomero, Eva; Barbadillo, María Carmen; Peña, Paloma García-de la; Ruiz, Lucía; López-Robledillo, Juan Carlos; Moruno, Henry; Pérez, Ana; Cobo‐Ibáñez, Tatiana; Almodóvar, Raquel; Lojo, L.; Monteagudo, I.; Yébenes, María Jesús García-De; López‐Longo, Francisco Javier

doi:10.1016/j.reumae.2016.07.012

Cited by 10 publications

(11 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The proportion of patients with glucocorticoid prescriptions was very similar to that found by Salazar et al in two high-complexity institutions in Colombia (81.3%) [ 17 ] and by Smoyer et al in the USA (72.7%) [ 12 ] but was higher than that found in the EuroMyositis Registry (31.6%) [ 9 ] and in the last consultation of the Myopathies Registry of the Community of Madrid (REMICAM Cohort) (56.6%) [ 14 ]. Among the conventional DMARDs, azathioprine and methotrexate were the most commonly used, which is consistent with other reports [ 9 , 14 – 18 , 22 ]. Among the biological DMARDs, rituximab was the most commonly used, which is also consistent with the literature [ 9 , 12 , 14 , 17 , 18 , 22 ].…”

Section: Discussionsupporting

confidence: 91%

“…To the best of our knowledge, this is the largest study of patients with these pathologies in Colombia or Latin America. The median age of the patients was higher than that found in other studies (34.3-52.5 years) [9,[14][15][16][17][18], although a predominance of women was found in all such studies (63.3-69.0-82.7%) [9,[14][15][16][17][18][19][20]. On the other hand, the characterization of the main comorbidities was also consistent with that found in other publications [12,14,17,18,21].…”

Section: Discussionsupporting

confidence: 88%

“…The median age of the patients was higher than that found in other studies (34.3-52.5 years) [9,[14][15][16][17][18], although a predominance of women was found in all such studies (63.3-69.0-82.7%) [9,[14][15][16][17][18][19][20]. On the other hand, the characterization of the main comorbidities was also consistent with that found in other publications [12,14,17,18,21].…”

Section: Discussionsupporting

confidence: 88%

“…Among the biological DMARDs, rituximab was the most commonly used, which is also consistent with the literature [ 9 , 12 , 14 , 17 , 18 , 22 ]. On the other hand, among the immunosuppressants, a predominance of mycophenolate mofetil was found, which is consistent with findings in India [ 22 ] and the USA [ 12 ] but not with findings in other countries, where cyclophosphamide prevailed [ 14 , 15 , 17 , 18 ]. The differences in drug use patterns may be due to the characteristics of health systems, the accessibility and availability of drugs in each country, the management guidelines followed, the preferences of the prescriber, the marketing strategies of the pharmaceutical industry, the disease severity and complications, the type of myopathy, the disease course, and the patient tolerability to these drugs [ 6 , 11 , 24 ].…”

Section: Discussionsupporting

confidence: 88%

See 3 more Smart Citations

Autoimmune Idiopathic Inflammatory Myopathies: Pharmacological Differences and Similarities by Type of Myositis and by Sociodemographic Variables

Valladales‐Restrepo

Delgado-Araujo

Aristizábal-Carmona

et al. 2022

International Journal of Rheumatology

View full text Add to dashboard Cite

Objective. Autoimmune idiopathic inflammatory myopathies (IIMs) are a group of pathologies that are generally characterized by muscle weakness. Their treatment involves glucocorticoids and immunosuppressants. The aim was to identify differences and similarities in the pharmacological management of a group of patients with autoimmune IIMs according to the type of disease, sex, age group, and city of residence in Colombia from 2020 to 2021. Methods. This cross-sectional study identified medication prescription patterns for outpatient use in patients with autoimmune IIMs between 2020 and 2021 based on a population database of 8.5 million Colombians affiliated with the Colombian health system. Sociodemographic and pharmacological variables were considered. Results. A total of 671 patients with autoimmune IIMs were identified, with a median age of 57 years, and 70.9% were women. Overlap myositis was the most frequent disease (31.4%). A total of 91.5% of the patients received pharmacological treatment, mainly systemic glucocorticoids (78.5%), conventional disease-modifying antirheumatic drugs (DMARDs) (74.1%), immunosuppressants (9.1%), and biological DMARDs (3.7%). Pharmacological management predominated among patients with overlap myositis, those who lived in cities, and those affiliated with the contributory regime of the Colombian health system. Conventional DMARDs were prescribed mainly to women and to those older than 65 years. Conclusions. Patients with autoimmune IIMs are not treated homogeneously. The pattern of drug use varies according to the type of IIM, sex, age group, city, and health system regime affiliation.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 88%

Section: Discussionsupporting

confidence: 88%

Section: Discussionsupporting

confidence: 88%

See 2 more Smart Citations

Autoimmune Idiopathic Inflammatory Myopathies: Pharmacological Differences and Similarities by Type of Myositis and by Sociodemographic Variables

Valladales‐Restrepo

Delgado-Araujo

Aristizábal-Carmona

et al. 2022

International Journal of Rheumatology

View full text Add to dashboard Cite

show abstract

“…It does not contain any studies with animals performed by any of the authors and was approved by the regional ethics committees of all participating units. A full detailed description of the methodology and a report of the mortality of the overall series have been previously published …”

Section: Methodsmentioning

confidence: 99%

Overlap myositis, a distinct entity beyond primary inflammatory myositis: A retrospective analysis of a large cohort from the REMICAM registry

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background: Inflammatory idiopathic myositis (IIM) comprises a heterogeneous group of systemic muscular diseases that can occur together with other connective tissue diseases (CTD), named overlap myositis (OM). The question of whether OM is a distinct entity still remains controversial. Aim: The present study was conducted to assess the clinical and prognostic differences between patients diagnosed with OM, primary polymyositis (PM) and primary dermatomyositis (DM). Method: The study consists of a retrospective longitudinal and multicenter series of IIM patients. Patients were classified as OM, PM and DM. Overlap myositis was defined as patients fulfilling criteria for IIM plus criteria for other CTD (namely systemic sclerosis, systemic lupus erythematosus, mixed connective tissue disease, rheumatoid arthritis and primary Sjögren's syndrome).

show abstract

Incidence, Prevalence, and Mortality of Dermatomyositis: A Population‐Based Cohort Study

Kronzer

Kimbrough

Crowson

et al. 2022

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. We aimed to determine the population-based incidence, prevalence, and mortality of dermatomyositis (DM) using European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) criteria.Methods. This population-based cohort study included incident DM from January 1, 1995 to December 31, 2019. We manually reviewed all individuals with at least 1 code for DM or polymyositis to determine if they met EULAR/ ACR criteria, subspecialty physician diagnosis, and/or Bohan and Peter criteria. We age-and sex-adjusted incidence and prevalence estimates to the US non-Hispanic White year 2000 population and estimated prevalence on January 1, 2015. Standardized mortality ratios (SMRs) with 95% confidence intervals (95% CIs) compared observed to expected mortality adjusting for age, sex, and year.Results. We identified 40 cases of verified DM, with 29 cases incident in Olmsted County from 1995 to 2019. The mean age was 57 years, 26 (90%) were female, and 12 (41%) had clinically amyopathic DM (CADM). The median follow-up time was 8.2 years. The overall adjusted incidence of DM was 1.1 (95% CI 0.7-1.5) per 100,000 person-years, and prevalence was 13 (95% CI 6-19) per 100,000. The SMR was significantly elevated among the myopathic DM cases (3.1 [95% CI 1.1-6.8]) but not CADM cases (1.1 [95% CI 0.2-3.3]). The positive predictive value of ≥2 DM codes was only 40 of 82 (49%).Conclusion. This population-based study found that DM incidence and prevalence were higher than previously reported. Mortality was significantly elevated for myopathic DM but not for CADM.The content herein is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

show abstract

Multicenter Registry on Inflammatory Myositis From the Rheumatology Society in Madrid, Spain: Descriptive Analysis

Cited by 10 publications

References 25 publications

Autoimmune Idiopathic Inflammatory Myopathies: Pharmacological Differences and Similarities by Type of Myositis and by Sociodemographic Variables

Autoimmune Idiopathic Inflammatory Myopathies: Pharmacological Differences and Similarities by Type of Myositis and by Sociodemographic Variables

Overlap myositis, a distinct entity beyond primary inflammatory myositis: A retrospective analysis of a large cohort from the REMICAM registry

Incidence, Prevalence, and Mortality of Dermatomyositis: A Population‐Based Cohort Study

Contact Info

Product

Resources

About